Numerous studies have implicated the crosstalk between EGFR and AMPK signaling in EGFR-TKI sensitivity and demonstrated the autophagy induction accompanied with AMPK activation after erlotinib or gefitinib treatment in EGFR mutant NSCLC cells (Chang et al., 2014; Li et al., 2013; Whang et al., 2016; Zhang et al., 2014). This evidence concerns the gene PRKAA2 and non-small cell lung carcinoma.